Pre-workout supplements present compound compliance challenges: ingredient safety issues (stimulants and novel compounds that may lack NDI notifications or safe use evidence), claim issues (performance outcome claims that may not be substantiated at the doses used), and marketing issues (aggressive imagery and language that implies drug-level effects). Handling each of these correctly requires understanding the separate regulatory frameworks that apply.
What FDA Permits for Pre-Workout Claims
Under 21 CFR 101.93(f), structure/function claims for pre-workout supplements may describe support for normal exercise performance:
"Supports healthy energy levels during exercise"
"Promotes endurance and stamina"
"Supports healthy muscle function during exercise"
"Promotes focus and mental alertness during workouts"
"Supports healthy blood flow during exercise"
"Promotes healthy nitric oxide production"
"Helps maintain hydration during physical activity"
"Supports recovery from exercise-induced muscle fatigue"
These claims describe support for normal physical function. They don't imply treatment of fatigue disorders, cardiovascular disease, or metabolic conditions.
Where Pre-Workout Claims Cross the Line
Prohibited disease and drug claims:
"Treats chronic fatigue" — chronic fatigue syndrome is a named disease
"Improves cardiovascular performance in people with heart conditions" — disease population targeting
"Enhances oxygen delivery in people with poor circulation" — implies treatment of vascular disease
"Clinically proven to increase testosterone" — disease-level outcome claim for a hormone
"Works like a controlled substance" — drug comparison
"Legal alternative to [banned substance]" — drug comparison; implies equivalent pharmacological effect
Stimulant Ingredients: Ingredient-Level Risk
Pre-workout supplements frequently contain stimulant ingredients where the compliance issue is not just claim language but the ingredient itself:
Caffeine: Generally recognized as safe (GRAS) at doses used in conventional foods; at high doses in concentrated supplements (200mg+ per serving), safety questions have been raised particularly for at-risk populations. FDA issued a guidance document in 2018 warning about pure and highly concentrated caffeine products.
DMAA (1,3-dimethylamylamine): FDA has taken the position that DMAA is not a lawful dietary supplement ingredient — it is not a constituent of the geranium plant as some manufacturers claimed, and FDA has issued multiple warning letters citing DMAA-containing products as adulterated. Using DMAA in a supplement is an ingredient legality issue, independent of claims.
DMHA and other DMAA analogs: Novel stimulants introduced as DMAA alternatives have faced similar FDA scrutiny. Several have received warning letters. New stimulant compounds without NDI notifications or established safety records carry both ingredient and claim risk.
Synephrine (bitter orange): Has an established market history as a dietary supplement ingredient. Structure/function claims about supporting energy metabolism are potentially permissible. Claims about "fat burning" or "thermogenic" effects implying weight loss treatment carry the same disease claim risks as any weight management product.
Beta-alanine: Generally well-tolerated with good clinical evidence for buffering exercise-induced muscle fatigue. Structure/function claims about supporting muscle endurance during high-intensity exercise are potentially supportable at standard doses (3.2–6.4g/day).
Serving Size and Dose Disclosure
Pre-workout supplements are sometimes sold in concentrated forms with small serving sizes. If the serving size on the label doesn't reflect the amount consumers actually use — particularly when products are commonly "scooped" at multiples of the stated serving size — there may be a serving size accuracy issue under 21 CFR 101.36. Accurate serving size disclosure is particularly important for stimulant-containing products where dose matters for safety.
FTC Claims in Pre-Workout Marketing
Pre-workout brands make performance claims across advertising, influencer content, and social media that often exceed what the product can substantiate. Under FTC Act Section 5, specific performance outcome claims ("increases strength by X%," "boosts endurance for 60 minutes") require competent and reliable scientific evidence at the dose and formulation in the actual product. Generic clinical literature for individual ingredients doesn't automatically substantiate specific outcome claims for a multi-ingredient formulation.
Pre-workout compliance requires both ingredient-level review and claim-level scanning
Truli reviews pre-workout supplement labels and marketing materials for stimulant ingredient legal status, structure/function claim compliance under 21 CFR 101.93, and FTC substantiation issues — flagging novel stimulants that may require NDI notification and performance claims that aren't supported by the ingredient evidence at the doses used.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
